Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

Inclusion Criteria: * Capable of giving signed informed consent * Patients aged \>18 years at the time of signing the informed consent form (ICF) * Patients with nasal polyps in the setting of suspected AFRS and electing to undergo comprehensive sinus surgery per established criteria * Diagnosis of nasal polyps by consensus criteria * Failure of appropriate medical therapy, including topical intranasal corticosteroid (spray or irrigation) \> 8 weeks duration, systemic corticosteroid trial of 1-3 weeks duration, and nasal saline irrigation of \> 4 weeks duration * A minimum SNOT-22 score of 20 at the time of enrollment * A minimum CT Lund-MacKay score of \> 1 at the time of enrollment * Suspected AFRS based on Bent and Kuhn criteria * Patients meet 3/5 criteria at the time of enrollment and 5/5 criteria at time of randomization: environmental atopy by skin or serum testing, nasal polyposis, characteristic CT findings, eosinophilic mucous, fungal identification on histopathology Exclusion Criteria: * Patients who have undergone nasal or sinus surgery within 3 months prior to enrollment * Patients with conditions or comorbid disease findings that exclude nasal endoscopy for evaluation of primary outcomes, such as current rhinitis medicamentosa, nasal cavity tumors, occlusive septal deviation following surgery * Clinically important comorbidities that may confound the interpretation of clinical efficacy, including aspirin-exacerbated respiratory disease, cystic fib…